KR20230148855A - 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템 - Google Patents

생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템 Download PDF

Info

Publication number
KR20230148855A
KR20230148855A KR1020237034773A KR20237034773A KR20230148855A KR 20230148855 A KR20230148855 A KR 20230148855A KR 1020237034773 A KR1020237034773 A KR 1020237034773A KR 20237034773 A KR20237034773 A KR 20237034773A KR 20230148855 A KR20230148855 A KR 20230148855A
Authority
KR
South Korea
Prior art keywords
antibody
binding
peptide
immuno
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237034773A
Other languages
English (en)
Korean (ko)
Inventor
홍강 쿠이
이 리
쑤언쿠오 쑤
라이 린 락
정지안 리
Original Assignee
더 존스 홉킨스 유니버시티
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티, 브리스톨-마이어스 스큅 컴퍼니 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20230148855A publication Critical patent/KR20230148855A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/24—Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28023—Fibres or filaments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
KR1020237034773A 2017-03-30 2018-03-28 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템 Ceased KR20230148855A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762478886P 2017-03-30 2017-03-30
US62/478,886 2017-03-30
KR1020197031323A KR102660861B1 (ko) 2017-03-30 2018-03-28 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
PCT/US2018/024721 WO2018183417A1 (en) 2017-03-30 2018-03-28 A supramolecular high affinity protein-binding system for purification of biomacromolecules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031323A Division KR102660861B1 (ko) 2017-03-30 2018-03-28 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템

Publications (1)

Publication Number Publication Date
KR20230148855A true KR20230148855A (ko) 2023-10-25

Family

ID=63678187

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237034773A Ceased KR20230148855A (ko) 2017-03-30 2018-03-28 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
KR1020197031323A Active KR102660861B1 (ko) 2017-03-30 2018-03-28 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197031323A Active KR102660861B1 (ko) 2017-03-30 2018-03-28 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템

Country Status (6)

Country Link
US (3) US11359005B2 (https=)
EP (1) EP3601362A4 (https=)
JP (2) JP7229169B2 (https=)
KR (2) KR20230148855A (https=)
CN (2) CN110741017B (https=)
WO (1) WO2018183417A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3601362A4 (en) * 2017-03-30 2020-12-16 The Johns Hopkins University HIGH AFFINITY PROTEIN SUPRAMOLECULAR BINDING SYSTEM FOR BIOMACROMOLECULES PURIFICATION
WO2019036631A1 (en) * 2017-08-18 2019-02-21 The Johns Hopkins University SUPRAMOLECULAR FILAMENT ASSEMBLIES FOR THE PURIFICATION OF PROTEINS
US20210130395A1 (en) * 2018-05-11 2021-05-06 William Marsh Rice University Proximity induced site-specific antibody conjugation
CN114225020B (zh) * 2021-12-31 2023-05-02 暨南大学 一种ova淀粉样蛋白原纤维及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2006123829A1 (ja) 2005-05-17 2006-11-23 Sapporo Medical University ＰＡＰ２ａに対する抗体ならびにその診断的および治療的使用
US8551781B2 (en) 2009-11-19 2013-10-08 The Regents Of The University Of California Vault complexes for facilitating biomolecule delivery
EP3601362A4 (en) * 2017-03-30 2020-12-16 The Johns Hopkins University HIGH AFFINITY PROTEIN SUPRAMOLECULAR BINDING SYSTEM FOR BIOMACROMOLECULES PURIFICATION
WO2019036631A1 (en) * 2017-08-18 2019-02-21 The Johns Hopkins University SUPRAMOLECULAR FILAMENT ASSEMBLIES FOR THE PURIFICATION OF PROTEINS

Also Published As

Publication number Publication date
US20260049121A1 (en) 2026-02-19
KR102660861B1 (ko) 2024-04-25
CN110741017A (zh) 2020-01-31
JP2023011689A (ja) 2023-01-24
JP7229169B2 (ja) 2023-02-27
US11359005B2 (en) 2022-06-14
WO2018183417A1 (en) 2018-10-04
US20200062827A1 (en) 2020-02-27
US12466875B2 (en) 2025-11-11
US20230050031A1 (en) 2023-02-16
KR20190138648A (ko) 2019-12-13
CN110741017B (zh) 2023-08-29
EP3601362A1 (en) 2020-02-05
JP2020512385A (ja) 2020-04-23
CN117024534A (zh) 2023-11-10
EP3601362A4 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
US11292841B2 (en) Anti-PD-1 nano-antibody and application thereof
JP2023011689A (ja) 生体高分子の精製のための超分子高アフィニティタンパク質結合系
CN105722855B (zh) 恒定链经修饰的双特异性五价和六价Ig-M抗体
JP7794789B2 (ja) タンパク質精製のための超分子フィラメント集合体
KR101151805B1 (ko) 바이포달 펩타이드 바인더
WO2017157334A1 (zh) 抗pd-l1纳米抗体及其编码序列和用途
WO2024046239A1 (zh) 靶向人gprc5d的重组人源化单克隆抗体及其应用
TW200825103A (en) Novel polypeptides and uses thereof
CN104098698A (zh) 一种抗cd3抗体及其制法和应用
US11306147B2 (en) Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
RU2478645C2 (ru) Растворимый мутант рецептора фактора некроза опухоли
TW201102086A (en) Antibodies against human CCN1 and uses thereof
JP2023548345A (ja) クリッピング率の低減した抗原結合ドメイン
JP2023547661A (ja) Ｃｄ３に結合するポリペプチド構築物
CN113912716B (zh) 针对α-突触核蛋白抗原的抗体及其应用
CA3124195A1 (en) Fusion protein with a toxin and scaffold protein
AU765990B2 (en) Structural models for cytoplasmic domains of transmembrane receptors
KR20240038740A (ko) 결합-촉발된 항체 침전 및 정제를 위한 고친화성 초분자 중합체
TW202506726A (zh) 雙特異性工程化抗體
CN115583995A (zh) 双特异性抗体及其制备方法和应用
WO2023011650A1 (zh) 一种多特异性抗体及其用途
CN115991785A (zh) 一种双特异性抗体、制备方法和用途
WO2011132940A2 (ko) Rtk에 특이적으로 결합하는 rtk-bpb
KR20110116930A (ko) 이온채널에 특이적으로 결합하는 이온채널―ｂｐｂ
WO2012122519A2 (en) Ligands to the membrane protein caveolin

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601